Company Overview of U.S. Centers For Disease Control And Prevention (cdc)
1600 Clifton Road Ne
Atlanta, GA 30329
Key Executives for U.S. Centers For Disease Control And Prevention (cdc)
Director of Coordinating Center for Health Promotion
Principal Deputy Director
Associate Director of Science
Compensation as of Fiscal Year 2016.
U.S. Centers For Disease Control And Prevention (cdc) Key Developments
GeoVax Labs Enters into Research Collaboration Agreement with Centers for Disease Control and Prevention
Apr 11 16
GeoVax Labs entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine. The company announced that it had begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform, and that it had entered into a collaborative relationship with researchers at the University of Georgia to speed development of the vaccine. The research collaboration agreement between GeoVax and the CDC should further broaden and accelerate the company's Zika vaccine development through access to Zika virus antibodies available at the CDC and testing of vaccine candidates by the CDC in appropriate animal models.
Evolva Signs License Agreement with the US Centers for Disease Control and Prevention to Develop and Commercialise Nootkatone Globally for Pest Control
Apr 5 16
Evolva announced that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control of a wide range of disease and virus vectors such as ticks, mosquitoes, fleas, flies, lice, bed bugs, and other biting insects. This expanded focus is included in the comprehensive Cooperative Research and Development Agreement (CRADA) now in place between Evolva and the CDC. Nootkatone could play an important role in the global response to the spread of Zika. CDC research has shown nootkatone both repels and kills the yellow fever mosquito, Aedes aegypti, and the black-legged tick, Ixodes scapularis which transmits Lyme disease. Nootkatone appears to have a mode of action distinct from that of currently used pesticides and therefore could potentially be valuable for mitigating pesticide resistance in mosquito vectors. Nootkatone already occurs in the natural environment and has an established track record as a flavor and fragrance ingredient, providing attractive characteristics in a number of respects. Nootkatone can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the Nootka cypress), or produced on an industrial scale from brewing via yeast fermentation. Evolva is currently performing all necessary safety and efficacy studies to get nootkatone approved by the US Environmental Protection Agency, initially as a repellent against the blacklegged tick.
GeoVax Labs Inc. Enters into Research Collaboration Agreement with Centers for Disease Control and Prevention
Mar 30 16
GeoVax Labs Inc. announced that it has entered into a Research Collaboration Agreement with the Centers for Disease Control and Prevention (CDC) to evaluate the immunogenicity and protective efficacy of its Zika virus vaccine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries